Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Guanghai Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7508-274X; OpenAlex author ID A5051014138. Sources: ClinicalTrials.gov.

Their work

Papers
31 (first author 0, last author 22)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2014: 1 trial · 2015: none · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers, 1 trial · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 5 papers · 2025: 3 papers · 2026: 2 papers

Papers 31

  1. Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/cam4.72378↗
  2. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  3. Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicohort Study. Co-author DOI 10.1097/sla.0000000000006610↗
  4. Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy. Last author DOI 10.3389/fimmu.2025.1487318↗
  5. Association of lung immune prognostic index with overall survival in pancreatic ductal adenocarcinoma patients treated using chemotherapy. Last author DOI 10.7150/ijms.102404↗
  6. Corrections to: “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signall… Co-author DOI 10.1002/ctm2.70158↗
  7. A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2024.03.017↗
  8. Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy. Last author DOI 10.1080/21645515.2024.2376429↗
  9. Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer. Last author DOI 10.1186/s12885-024-11823-8↗
  10. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospect… Co-author DOI 10.1186/s12967-024-04989-z↗
  11. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic… Co-author DOI 10.1002/ctm2.1500↗
  12. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer. Last author DOI 10.1080/21645515.2023.2252692↗
  13. Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. Co-author DOI 10.1093/bjsopen/zrad031↗
  14. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02321-7↗
  15. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  16. S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Last author DOI 10.3389/fonc.2022.865404↗
  17. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma. Last author DOI 10.3389/fonc.2022.926260↗
  18. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. Last author DOI 10.3389/fsurg.2022.1002075↗
  19. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer. Last author DOI 10.1186/s12864-021-08097-w↗
  20. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer. Last author DOI 10.1186/s12885-021-08943-w↗
  21. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer Last author DOI 10.21203/rs.3.rs-215080/v1↗
  22. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Last author DOI 10.12659/msm.927654↗
  23. The Correlation Analysis of Baseline Serum CA199, CEA and CA125 in Patients with Advanced Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-18126/v1↗
  24. Correlation Between Baseline Serum Tumor Markers and Clinical Characteristic Factors in Patients with Advanced Pancreatic Cancer. Last author DOI 10.2147/ott.s269720↗
  25. CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer. Last author DOI 10.1186/s12885-019-6078-2↗
  26. Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/tcr.2018.12.20↗
  27. Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection. Last author DOI 10.21037/tcr.2019.04.24↗
  28. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based … Last author DOI 10.1111/jcpt.12655↗
  29. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarc… Last author DOI 10.1038/s41598-017-00859-5↗
  30. Survival of patients with advanced pancreatic cancer after iodine125 seeds implantation brachytherapy: A meta-analysis. Last author DOI 10.1097/md.0000000000005719↗
  31. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Last author DOI 10.18632/oncotarget.21359↗

Trials 2

  1. PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer Principal investigator NCT04518800↗
  2. Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer Principal investigator NCT02124317↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guochao Deng · 11 shared papers, 2019–2026 · strength 2.14
  2. Quanli Han · 12 shared papers, 2017–2025 · strength 1.99
  3. Lei Huang · 6 shared papers, 2022–2025 · strength 1.26
  4. Yan Xia Shi · 7 shared papers, 2017–2025 · strength 1.21
  5. Shiyun Chen · 3 shared papers, 2023–2025 · strength 0.90
  6. Shasha Guan · 5 shared papers, 2019–2024 · strength 0.80
  7. Yue Ma · 2 shared papers, 2024–2026 · strength 0.61
  8. Ru Jia · 2 shared papers, 2024–2025 · strength 0.54
  9. Yue Ma · 2 shared papers, 2024 · strength 0.50
  10. Mengjiao Fan · 2 shared papers, 2024–2026 · strength 0.49
  11. Liangchao Zhao · 2 shared papers, 2023–2025 · strength 0.47
  12. Mancang Gu · 2 shared papers, 2023–2024 · strength 0.42
  13. Kaidi Chen · 2 shared papers, 2023–2024 · strength 0.42
  14. Qian Zhou · 2 shared papers, 2021–2022 · strength 0.37
  15. Nan Zhang · 1 shared paper, 2025 · strength 0.33
  16. Chunyi Hao · 2 shared papers, 2022–2026 · strength 0.32
  17. Jiujie Cui · 2 shared papers, 2022–2026 · strength 0.32
  18. Nan Zhang · 1 shared paper, 2025 · strength 0.30
  19. Mengjiao Fan · 1 shared paper, 2024 · strength 0.26
  20. Yang Chen · 2 shared papers, 2019 · strength 0.24
  21. Wei Li · 1 shared paper, 2026 · strength 0.23
  22. Haitao Zhang · 1 shared paper, 2026 · strength 0.23
  23. Guang Tan · 1 shared paper, 2026 · strength 0.23
  24. Ke Cheng · 1 shared paper, 2026 · strength 0.23
  25. Liwei Wang · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.